US Patent Issued to ImmunityBio on Feb. 3 for "Chemokine responsive activated natural killer cells with secondary homing activation for verified targets" (California Inventors)

ALEXANDRIA, Va., Feb. 3 -- United States Patent no. 12,540,170, issued on Feb. 3, was assigned to ImmunityBio Inc. (San Diego).

"Chemokine responsive activated natural killer cells with secondary homing activation for verified targets" was invented by Nathan Schomer (San Diego), Laurent Boissel (San Diego) and Hans Klingemann (San Diego).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are...